ACCESS Newswire·Nov 11, 2026, 5:30 PM ET

The DEA Just Fenced In State Medical Marijuana Operators, One State at a Time

On October 30, 2026, the DEA began issuing federal registrations to state-licensed medical marijuana dispensaries following the April 2026 rescheduling Order.
These federal registrations do not authorize the transport of marijuana across state lines because they are strictly limited to the scope of the holder's individual state license.
Under 21 C.F.R. § 1301.13(k), a registrant may act only subject to state license limitations, meaning a license in one state does not grant authority in another.
Interstate shipments of state-licensed marijuana are now unauthorized distribution under 21 U.S.C. § 841(a)(1) because they exceed the boundaries of the federal registration.
Unlike other Schedule III drugs such as ketamine or testosterone, state-licensed marijuana cannot enter the national distribution system due to state-specific registration caps.
The FDA remains the only pathway for a national cannabinoid market, as FDA-approved marijuana drugs face no state-license restrictions or Federal Food, Drug, and Cosmetic Act barriers.
The Federal Food, Drug, and Cosmetic Act prohibits introducing unapproved new drugs into interstate commerce, which continues to block state-licensed products from crossing state borders.
Investors should recognize that the Order improves state-level economics through tax relief & federal cover but does not create a unified national market.
Legal experts confirm that congressional action is required to authorize commercial interstate cannabis trade between states.
MMJ International Holdings is pursuing FDA-regulated treatments for Huntington's disease & multiple sclerosis exclusively through federal pathways.

Company: MMJ International Holdings
Keywords: Healthcare & Pharmaceutical, Company Update